Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.48 |
| ▸ | PDCD1 | Q15116 | 7/20 | 0.36 |
| ▸ | CD274 | Q9NZQ7 | 7/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 3/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30432719 | 1.00 | SSTR4 (0.48) | SSTR4PDCD1CD274HDAC1HDAC3 | |
| SCHEMBL25167443 | 0.88 | PDCD1 (0.39) | SSTR4PDCD1CD274HDAC1HDAC3 | |
| SCHEMBL21412369 | 0.83 | PDCD1 (0.53) | SSTR4PDCD1CD274 | |
| SCHEMBL29983207 | 0.83 | PDCD1 (0.53) | SSTR4PDCD1CD274 | |
| SCHEMBL23727037 | 0.78 | PDCD1 (0.33) | SSTR4PDCD1CD274 | |
| SCHEMBL28903198 | 0.77 | SSTR4 (0.50) | SSTR4PDCD1CD274HDAC1HDAC3 | |
| SCHEMBL6510214 | 0.76 | SSTR4 (0.57) | SSTR4HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL23725652 | 0.76 | PDCD1 (0.31) | SSTR4PDCD1CD274 | |
| Lithium Ion SCHEMBL23726796 | 0.75 | SSTR4 (0.48) | SSTR4PDCD1CD274HDAC1HDAC3 | |
| SCHEMBL30836724 | 0.75 | PDCD1 (0.46) | SSTR4PDCD1CD274HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORP (US) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230143612-A1 | SUBSTITUTED 1,1'-BIPHENYL COMPOUNDS AND METHODS USING SAME | HAVCR2, HMBS, VHL | SSTR4 3227/4885PDCD1 62/4885CD274 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.